Citi lowered the firm’s price target on Sight Sciences (SGHT) to $4 from $4.50 and keeps a Neutral rating on the shares. The firm is cautious on medical technology entering the Q3 earnings season. Citi believes the outcome of the Section 232 investigation into medical equipment and devices will take time.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- Sight Sciences Amends Loan Agreement with Hercules
- Sight Sciences announces publication of results on OMNI Surgical System
- Sight Sciences: Balancing Resilience in Glaucoma Market with Reimbursement Challenges – Hold Rating Justified
- Needham medtech & diagnostics analysts hold analyst/industry conference call
- Sight Sciences OMNI Surgical System to be included in UnitedHealthcare coverage